Murray Stahl's NTLA Position Overview
Murray Stahl (via Horizon Kinetics Asset Management LLC) currently holds 13,792 shares of Intellia Therapeutics, Inc. (NTLA) worth $123,990, representing 0.00% of the portfolio. First purchased in 2020-Q2, this long-term strategic position has been held for 23 quarters.
Based on 13F filings, Murray Stahl has maintained a strategic position in NTLA, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2023, adding 5,000 shares. Largest reduction occurred in Q2 2025, reducing 804 shares.
Analysis based on 13F filings available since 2013 Q2
Murray Stahl's Intellia Therapeutics (NTLA) Holding Value Over Time
Track share changes against reported price movement
Quarterly Intellia Therapeutics (NTLA) Trades by Murray Stahl
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -604 | Reduce 4.20% | 13,792 | $8.99 |
| Q3 2025 | +604 | Add 4.38% | 14,396 | $17.27 |
| Q2 2025 | -804 | Reduce 5.51% | 13,792 | $9.38 |
| Q1 2025 | +200 | Add 1.39% | 14,596 | $7.11 |
| Q4 2024 | +604 | Add 4.38% | 14,396 | $11.66 |
| Q3 2024 | -604 | Reduce 4.20% | 13,792 | $20.55 |
| Q4 2023 | -604 | Reduce 4.03% | 14,396 | $30.49 |
| Q1 2023 | +5,000 | Add 50.00% | 15,000 | $37.27 |
| Q2 2020 | +10,000 | New Buy | 10,000 | $21.00 |
Murray Stahl's Intellia Therapeutics Investment FAQs
Murray Stahl first purchased Intellia Therapeutics, Inc. (NTLA) in Q2 2020, acquiring 10,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Murray Stahl has held Intellia Therapeutics, Inc. (NTLA) for 23 quarters since Q2 2020.
Murray Stahl's largest addition to Intellia Therapeutics, Inc. (NTLA) was in Q2 2020, adding 10,000 shares worth $210,000.
According to the latest 13F filing for Q4 2025, Murray Stahl's firm, Horizon Kinetics Asset Management LLC, owns 13,792 shares of Intellia Therapeutics, Inc. (NTLA), valued at approximately $123,990.
As of the Q4 2025 filing, Intellia Therapeutics, Inc. (NTLA) represents approximately 0.00% of Murray Stahl's publicly disclosed stock portfolio, making it one of their key holdings.
Murray Stahl's peak holding in Intellia Therapeutics, Inc. (NTLA) was 15,000 shares, as reported at the end of Q1 2023.